---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-001104"
form_type: "8-K"
ticker: "NEPH"
cik: "0001196298"
company_name: "NEPHROS INC"
filed_at: "2022-01-13T23:59:59+00:00"
generated_at: "2026-06-27T18:09:18.742478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nephros reports record FY2021 revenue of $10.4M, guides FY2022 $13-13.5M

## Summary
- Preliminary FY2021 net revenue $10.4M (+21% YoY); Q4 revenue $2.8M (+18% YoY).
- Issued FY2022 revenue guidance of $13.0M to $13.5M, representing 25-30% growth.
- Ended Q4 2021 with ~$7M cash; reinstated revenue guidance practice.
- Pathogen Detection Systems revenue $188k in 2021; expects >200% growth in 2022.
- Subsidiary SRP received FDA info request for HDF Assist; expects 510(k) clearance H1 2022.

## SEC filing metadata
- accession: 0001493152-22-001104
- form_type: 8-K
- ticker: NEPH
- cik: 0001196298
- company_name: NEPHROS INC
- filed_at: 2022-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1196298/000149315222001104/0001493152-22-001104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1196298/000149315222001104/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-001104
- JSON: https://secwatch.observer/filing/0001493152-22-001104.json
- Plain text: https://secwatch.observer/filing/0001493152-22-001104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.